Tiller KE, Tessier PM (2015) Advances in antibody design. Annu Rev Biomed Eng 17(1):191–216

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Z, Kankala RK, Yang Z, Li W, Xie S, Li H, Chen A-Z, Zou L (2022) Antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects. Theranostics 12(8):3719

Article  CAS  PubMed  PubMed Central  Google Scholar 

Junghans RP (1997) Finally! The Brambell receptor (FcRB) Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 16:29–57

Article  CAS  PubMed  Google Scholar 

Antohe F, Rădulescu L, Gafencu A, Gheţie V, Simionescu M (2001) Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol 62(2):93–105

Article  CAS  PubMed  Google Scholar 

Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715–725

Article  CAS  PubMed  Google Scholar 

Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687–709

Article  CAS  PubMed  Google Scholar 

Fan Y-Y, Farrokhi V, Caiazzo T, Wang M, O’Hara DM, Neubert H (2019) Human FcRn tissue expression profile and half-life in PBMCs. Biomolecules 9(8):373

Article  CAS  PubMed  PubMed Central  Google Scholar 

Proctor JR, Wong H (2024) Time-dependent clearance can confound exposure-response analysis of therapeutic antibodies: a comprehensive review of the current literature. Clin Transl Sci 17(1):13676

Article  Google Scholar 

Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W (2003) PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model. Biosilico 1(4):121–124

Article  CAS  Google Scholar 

Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67–86

Article  CAS  PubMed  Google Scholar 

Liu L (2018) Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 9(1):15–32

Article  CAS  PubMed  Google Scholar 

Niederalt C, Kuepfer L, Solodenko J, Eissing T, Siegmund H-U, Block M, Willmann S, Lippert J (2018) A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. J Pharmacokinet Pharmacodyn 45:235–257

Article  CAS  PubMed  Google Scholar 

Glassman PM, Balthasar JP (2019) Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Drug Metab Pharmacokinet 34(1):3–13

Article  CAS  PubMed  Google Scholar 

Witte WEA, Avery LB, Mackness BC, Bogaert T, Park A, Sargentini-Maier ML (2023) Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules. J Pharmacokinet Pharmacodyn 50(3):229–241

Article  PubMed  Google Scholar 

Patsatzis DG, Wu S, Shah DK, Goussis DA (2022) Algorithmic multiscale analysis for the FcRn mediated regulation of antibody PK in human. Sci Rep 12(1):1–21

Article  Google Scholar 

Kátai CB, Smithline SJ, Thalhauser CJ, Bosgra S, Elassaiss-Schaap J (2024) An asymptotic description of a basic FcRn-regulated clearance mechanism and its implications for PBPK modelling of large antibodies. J Pharmacokinet Pharmacodyn 1–25

Gurbaxani B, Cruz LLD, Chintalacharuvu K, Morrison SL (2006) Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 43(9):1462–1473

Article  CAS  PubMed  Google Scholar 

Gurbaxani B, Dostalek M, Gardner I (2013) Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol 56(4):660–674

Article  CAS  PubMed  Google Scholar 

Kelly RL, Yu Y, Sun T, Caffry I, Lynaugh H, Brown M, Jain T, Xu Y, Wittrup KD (2016) Target-independent variable region mediated effects on antibody clearance can be FcRn independent. In: MAbs, vol. 8, pp 1269–1275. Taylor & Francis

Fuhrmann S, Kloft C, Huisinga W (2017) Impact of altered endogenous IgG on unspecific mAb clearance. J Pharmacokinet Pharmacodyn 44:351–374

Article  CAS  PubMed  Google Scholar 

Kátai CB, Smithline SJ, Thalhauser CJ, Bosgra S, Elassaiss-Schaap J (2024) An asymptotic description of a basic FcRn-regulated clearance mechanism and its implications for PBPK modelling of large antibodies. In: PAGE2024 Poster Presentation. https://www.page-meeting.org/default.asp?abstract=11153. Accessed 24 Jan 2025

Stader F, Liu C, Derbalah A, Momiji H, Pan X, Gardner I, Jamei M, Sepp A (2024) A physiologically based pharmacokinetic model relates the subcutaneous bioavailability of monoclonal antibodies to the saturation of FcRn-mediated recycling in injection-site-draining lymph nodes. Antibodies 13(3):70

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56(3):248–252

Article  CAS  PubMed  Google Scholar 

Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507–532

Article  CAS  PubMed  Google Scholar 

Peletier LA, Gabrielsson J (2012) Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn 39(5):429–451

Article  PubMed  PubMed Central  Google Scholar 

Kristiansen KU (2019) Geometric singular perturbation analysis of a dynamical target mediated drug disposition model. J Math Biol 79(1):187–222

Article  PubMed  Google Scholar 

Gabrielsson J, Hjorth S (2023) Turn on, tune in, turnover! Target biology impacts in vivo potency, efficacy, and clearance. Pharmacol Rev 75(3):416–462

Article  CAS  PubMed  Google Scholar 

Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589–1596

Article  CAS  PubMed  Google Scholar 

Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573–591

Article  CAS  PubMed  Google Scholar 

Grimm HP (2009) Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn 36:407–420

Article  CAS  PubMed  Google Scholar 

Aston PJ, Derks G, Raji A, Agoram BM, Graaf PH (2011) Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J Theor Biol 281(1):113–121

Article  CAS  PubMed  Google Scholar 

Aston PJ, Derks G, Agoram BM, Graaf PH (2014) A mathematical analysis of rebound in a target-mediated drug disposition model: I. Without feedback. J Math Biol 68:1453–1478

Article  PubMed  Google Scholar 

Patsatzis DG, Maris DT, Goussis DA (2016) Asymptotic analysis of a target-mediated drug disposition model: algorithmic and traditional approaches. Bull Math Biol 78:1121–1161

Article  CAS  PubMed  Google Scholar 

Chang H-Y, Wu S, Chowdhury EA, Shah DK (2022) Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system. J Pharmacokinet Pharmacodyn 49(3):337–362

Article  CAS